We also demonstrated that tasocitinib, a JAK3 inhibitor used clinically to treat rheumatoid arthritis (RA) and Crohn’s disease (CD), can reduce neuroinflammation and increase survival of Jak3−/+ heterozygotes in the ECM model [119]. This evidence concerns the gene JAK3 and Crohn disease.